Immunomedics, Inc.  

(Public, NASDAQ:IMMU)   Watch this stock  
Find more results for IMMU
4.08
-0.01 (-0.24%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.06 - 4.11
52 week 3.04 - 5.48
Open 4.09
Vol / Avg. 587,570.00/1.26M
Mkt cap 381.95M
P/E     -
Div/yield     -
EPS -0.50
Shares 93.39M
Beta 0.79
Inst. own 43%
May 5, 2015
Q3 2015 Immunomedics Inc Earnings Release (Estimated) Add to calendar
Feb 5, 2015
Q2 2015 Immunomedics Inc Earnings Call
Feb 4, 2015
Q2 2015 Immunomedics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -1143.38% -392.97%
Operating margin -1143.00% -393.52%
EBITD margin - -387.22%
Return on average assets -142.37% -74.48%
Return on average equity -209.24% -89.09%
Employees 120 -
CDP Score - -

Address

300 AMERICAN RD
MORRIS PLAINS, NJ 07950
United States - Map
+1-973-6058200 (Phone)
+1-973-6058282 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Using its technologies, the Company has built a pipeline of nine clinical-stage product candidates. Its advanced product candidate is 90Y-clivatuzumab tetraxetan. It initiated a Phase III registration trial in January 2014 in patients with advanced pancreatic cancer. Its portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs). Its advanced ADCs are IMMU-132 and IMMU-130, which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development.

Officers and directors

David M. Goldenberg Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Cynthia L. Sullivan President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Peter P. Pfreundschuh Chief Financial Officer, Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
Francois E. Wilhelm M.D., Ph.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Brian A. Markison Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Mary E. Paetzold Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard L. Sherman J.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Donald C. Stark Independent Director
Age: 60
Bio & Compensation  - Reuters